Clear Cell Renal Cell Carcinoma

Remaining challenges include uncertainty regarding the identification of predictive biomarkers, optimization of patient selection, and integration of combination or sequencing strategies. Beyond its immediate clinical impact, belzutifan establishes a foundation for next-generation hypoxia-targeted therapies.

In addition, pathway perturbation experiments further supported the contribution of DDR signaling to BMP5-associated cell fate regulation. Collectively, these findings suggest that BMP5 is associated with increased DNA damage burden and sustained DDR activation, which likely contribute to tumor-suppressive effects in ccRCC, highlighting its potential prognostic relevance and the possible therapeutic significance of BMP5-associated DDR signaling.

In the study, miR-1251-5p/MTHFD2 axis is shown to play a vital role in RCC. Therefore, targeting this axis may be a potential therapeutic target combating the progression of RCC.

Group CSTM testing was shown to be more valuable than single CSTM testing. The recommended test strategy includes CA242, CA199, CEA, AFP, SCC, and CA724.

P1, N=18, Not yet recruiting, Hrain Biotechnology Co., Ltd.

In conclusion, this study provides a comprehensive pan-cancer characterization of CHRNA7, offering novel insights into its potential role as a prognostic biomarker and immunotherapeutic target. These findings could facilitate the development of personalized cancer treatment strategies customized according to the expression level and functional status of CHRNA7.

P1, N=30, Recruiting, Chinese PLA General Hospital

Genomic analyses identified alterations in NF-κB-related genes, including CARD10 and IRAK1. A20/TNFAIP3 may exert cell-context-dependent effects in RCC and is associated with tumor-relevant transcriptional and genomic alterations requiring further validation.

However, most therapeutic data remain limited to preclinical models, and clinical validation is still lacking. This review synthesizes recent advances in molecular regulation and therapeutic targeting of DNL in ccRCC and discusses the challenges and future opportunities to improve mechanistic understanding and explore potential therapeutic applications.

Genetic testing confirmed sensitivity to dostarlimab-gxly and pembrolizumab, leading to the initiation of pembrolizumab (200 mg Q3W) and lenvatinib (20 mg QD) in June 2024 after spine surgery. We present a 57-year-old female patient initially diagnosed with FIGO Stage 2 EC, who subsequently developed distant metastases and was restaged as FIGO Stage 4B recurrent disease. The management of this patient illustrates the multimodal treatment approach and the critical role of molecular subtyping in guiding immunotherapeutic strategies for recurrent advanced EC.

The data presented here supports the concept that a ccRCC microenvironment may be driven by multiple modulatory mechanisms that allow immune escape to happen. Revealing the coordination of immune checkpoint molecules and the compensatory upregulation mechanisms may support future studies exploring multi-target immunotherapeutic strategies.

Proteogenomics is a crucial tool for refining disease taxonomy and identifying novel therapeutic vulnerabilities in ccRCC. By bridging the gap between genotype and functional phenotype, this integrated approach facilitates more precise risk stratification and accelerates the development of personalized medicine through better-informed selection of targeted and immune-based therapies.